Verschlimmbesserung: Craniospinal Radiotherapy is Essential in WNT Medulloblastoma Patients.

Standard-risk WNT medulloblastoma patients have an excellent prognosis (>90% progression free survival) using the combination of standard dose craniospinal radiotherapy (CSI) (23.4Gy) followed by platinum and alkylator based chemotherapy. A recent pilot study which attempted to completely omit radiotherapy was terminated early as all patients (n=3) relapsed rapidly (on treatment or within 6 months of completing treatment). The study highlights that therapy is the most important prognostic factor, with CSI still required to cure even the most favorable subgroup of medulloblastoma patients.